Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company’s recent ethics committee approval for a pilot cancer study. This approval represents the next step in Sona Nanotech's clinical development pathway, building on its current early feasibility study focused on late-stage melanoma patients. The early study, which is currently underway, involves 10 patients with late-stage melanoma for whom other treatments have failed. Results from this group are expected within t ...